Compare DexCom, Inc. (DXCM) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tapestry, Inc. — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Tapestry, Inc. trades at $116.27 (market cap $23.09B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1.6% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Tapestry, Inc. for 70 Days on average.
| DXCM | TPR | |
|---|---|---|
Market Cap | $31.86B | $23.09B |
Volume | 3,607,070 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $164.78 |
52-Week Low | $54.84 | $98.81 |
Typical Hold Time | 62 Days | 70 Days |
Enterprise Value | $31.32B | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
TPR trades at $116.24, up 2.51% today, showing strong momentum after recent earnings beats. The stock faces technical resistance near $117-119 but maintains bullish analyst support with a $174.64 consensus target. Recent financials show revenue growth to $7.01B in 2025, though net income declined to $183M. The company benefits from strong brand performance with Coach driving growth, while expanding digital presence through Google partnerships.
Outlook remains positive with 73% analyst buy ratings and projected 2026 revenue of $8B. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.93 P/E. The stock offers 50% upside to consensus target but requires monitoring of margin expansion and international growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
